Libtayo Approved for Advanced NSCLC With High PD-L1 Expression

Published by W Butcher on

The FDA approved cemiplimab-rwlc (Libtayo, Regeneron/Sanofi) for the first-line treatment of patients with metastatic or locally advanced or metastatic non-small cell lung cancer (NSCLC) that is unresectable and not amenable to definitive chemoradiation whose tumors have high PD-L1 expression and no EGFRALK or ROS1 aberrations.

Read More…

Categories: Uncategorized